Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to see if tocilizumab is safe and effective for treating systemic onset Juvenile Idiopathic Arthritis (soJIA). Another purpose is to see if tocilizumab helps reduce the amount of steroids (prednisone) needed to control symptoms of soJIA.


Clinical Trial Description

Systemic onset Juvenile Idiopathic Arthritis (soJIA) is a type of arthritis (inflammation of the joints) that occurs with other symptoms including fever, swollen lymph nodes (glands), rash, and body aches. Because soJIA can be difficult to treat, children with soJIA can have severe problems from long-term use of steroids (prednisone). These problems include low bone density (weak bones), fractures, failure to grow properly, and large weight gain. The arthritis that occurs in soJIA often causes damage to many joints. This can make it hard to move around or do basic tasks like dressing. Also, a life-threatening illness called Macrophage Activation Syndrome (MAS) can occur when starting, stopping, or changing drugs that are used to treat soJIA.

SoJIA can be hard to treat and many children with soJIA do not respond to drugs that work for other kinds of arthritis. Research doctors have studied a chemical signal called IL-6 that the body uses to manage inflammation. This signal has been found to be very high in patients with active soJIA. A drug called tocilizumab (TCZ) has been designed to block IL-6. For about 6 years, TCZ has been tested in Japan for treating soJIA. It is now being tested in studies in the United States. These studies can have very strict rules for enrolling patients. This trial is a single-patient research study for a subject who otherwise does not meet the rules for enrollment in ongoing trials. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00868751
Study type Interventional
Source Tufts Medical Center
Contact
Status Terminated
Phase N/A
Start date March 2009
Completion date June 2010

See also
  Status Clinical Trial Phase
Completed NCT00807846 - A Study To Evaluate The Effects Of Celecoxib (Celebrex®) Or Naproxen On Blood Pressure In Pediatric Subjects Phase 4
Completed NCT00279747 - A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA) Phase 3
Completed NCT00652925 - A Study to Evaluate the Efficacy and Safety of Celecoxib Suspension Compared to Naproxen Suspension in Patients With JRA Phase 3
Completed NCT02001844 - Foot Orthoses (FOs) on Pain, Quality of Life and the Gait With Children Diagnosed With JIA N/A
Completed NCT00731965 - Safety and Efficacy of Measles, Mumps, Rubella Vaccination in Juvenile Idiopathic Arthritis Phase 4
Completed NCT02067962 - Identification of Genes Involved in Juvenile Idiopathic Arthritis by Wholel Exome Sequencing N/A
Terminated NCT00637780 - Study To Determine The Pharmacokinetics Of Sulfasalazine In Children With Juvenile Idiopathic Arthritis Phase 4
Completed NCT00001614 - The Safety and Efficacy of Chicken Type II Collagen on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 1
Completed NCT01412021 - Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis
Enrolling by invitation NCT02377245 - Juvenile Inflammatory Rheumatism (JIR) Cohorte
Completed NCT00426218 - Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) Phase 1/Phase 2
Completed NCT00034853 - Meloxicam [Mobic] in Juvenile Rheumatoid Arthritis (JRA) Phase 3
Completed NCT06000566 - Drug Compliance and Affecting Factors in Juvenile Idiopathic Arthritis
Terminated NCT00511329 - Growth Hormone in Children With Juvenile Rheumatoid Arthritis (JRA) and With Crohn's Disease Phase 2/Phase 3
Terminated NCT00688545 - Naturalistic Safety Registry Of Celecoxib (CELEBREX(R)) And NSAIDs In Juvenile Idiopathic Arthritis
Recruiting NCT00012506 - The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis Phase 3